Alphatec Trims FY26 Outlook After Q3 Revenue Miss

Alphatec reported Q3 revenue below expectations, citing lower biologics attachment. It now expects FY26 revenue of about $862 million, adjusted EBITDA of about $137 million and free cash flow of about $10 million.